Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.

Hemolytic uremic syndrome (HUS) is a rare clinical and biological entity. HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens. Little information is available concerning the occurrence and outcome of this syndrome after administration of more recent chemotherapeutic agents. We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.